Compounding Pharmacies Market By Therapeutic Area (Pain Management, Hormone Replacement Therapy, Dermal Disorders, Nutritional Supplements, Others), By Route of Administration (Oral, Topical, Others), By Sterility (Non-Sterile Compounding Drugs, Sterile Compounding Drugs): Global Opportunity Analysis and Industry Forecast, 2021-2031
Compounding is preparation of a custom formulation of a medication to fit a unique need of a patient that cannot be met with commercially available products. They are able to make unique medications for each person as some people need drugs that are not available on the market. Compounding pharmacies can be of assistance in this situation since there are several potential causes for this need. Compounding pharmacies can create sterile and non-sterile chemicals. While some pharmacies may provide services for both types of compounding, others may only specialize in one. Injections, ocular drops, and infusions are examples of dosage forms that contain sterile substances.
The major factors that drive the growth of the global compound pharmacies market include increase in prevalence of chronic disease, high adoption of non-sterile medication, increase in old age population and improved life expectancy. In addition, growing drug failure rate, increase in popularity of personalized medicine and massive drug shortage across the globe is further propel the market growth during forecast period. However, increase in restrictions on manufacturing of complex formulation is likely to restrain the growth of the compounding pharmacies market during the forecast period. Conversely, growth potential of emerging economies is anticipated to provide numerous opportunities for market growth during the forecast period.
The compounding pharmacies market is segmented into therapeutic area, route of administration, sterility, and region. According to therapeutic area, the market is categorized into pain management, hormone replacement, dermal disorder, nutritional supplement and others. On the basis of route of administration, it is segmented into oral, topical and others. By end user, it is segregated into sterile compounding drugs and non-sterile compounding drugs. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include the Advance Pharmacy, Athenex pharma, B. Braun Melsungen AG, Dougherty's Pharmacy, Inc., Fresenius SE and Co. KGaA, Institutional pharmacy solutions, ITC compounding pharmacy, The McGuff Companies, Inc., Nephron pharmaceuticals, New Compounding Pharma, Olympia Pharmaceuticals, Panacea biomatx, Pencol compounding pharmacy, Perrigo Company plc, Rx express compounding pharmacy, RX3 compounding pharmacy, Valor Compounding Pharmacy.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the compounding pharmacies market analysis from 2021 to 2031 to identify the prevailing compounding pharmacies market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the compounding pharmacies market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global compounding pharmacies market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Therapeutic Area
Pain Management
Hormone Replacement Therapy
Dermal Disorders
Nutritional Supplements
Others
By Route of Administration
Oral
Topical
Others
By Sterility
Non-Sterile Compounding Drugs
Distribution Channel
Hospital Pharmacy
Compounding Pharmacy
Others
Sterile Compounding Drugs
Distribution Channel
Hospital Pharmacy
Compounding Pharmacy
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Italy
Spain
Rest of Europe
Germany
France
UK
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Advanced Pharmacy
Athenex Pharma Solutions
B. Braun Melsungen AG
Dougherty's Pharmacy, Inc.
Fresenius SE and Co. KGaA
Institutional pharmacy solutions
ITC compounding pharmacy
McGuff Companies, Inc.
Nephron pharmaceuticals
New Compounding Pharma
Olympia Compounding Pharmacy
Panacea Biomatx Inc (Triangle Compounding Pharmacy)
Pencol compounding pharmacy
Perrigo Company Plc (Fagron)
Rx express compounding pharmacy
RX3 compounding pharmacy
Valor Compounding Pharmacy
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Pain Management
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Hormone Replacement Therapy
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Dermal Disorders
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Nutritional Supplements
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Others
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- CHAPTER 5: COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oral
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Topical
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: COMPOUNDING PHARMACIES MARKET, BY STERILITY
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Non-Sterile Compounding Drugs
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.2.4 Non-Sterile Compounding Drugs Compounding Pharmacies Market by Distribution Channel
- 6.3 Sterile Compounding Drugs
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.3.4 Sterile Compounding Drugs Compounding Pharmacies Market by Distribution Channel
- CHAPTER 7: COMPOUNDING PHARMACIES MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Therapeutic Area
- 7.2.3 North America Market size and forecast, by Route of Administration
- 7.2.4 North America Market size and forecast, by Sterility
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Therapeutic Area
- 7.2.5.1.2 Market size and forecast, by Route of Administration
- 7.2.5.1.3 Market size and forecast, by Sterility
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Therapeutic Area
- 7.2.5.2.2 Market size and forecast, by Route of Administration
- 7.2.5.2.3 Market size and forecast, by Sterility
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Therapeutic Area
- 7.2.5.3.2 Market size and forecast, by Route of Administration
- 7.2.5.3.3 Market size and forecast, by Sterility
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Therapeutic Area
- 7.3.3 Europe Market size and forecast, by Route of Administration
- 7.3.4 Europe Market size and forecast, by Sterility
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Therapeutic Area
- 7.3.5.1.2 Market size and forecast, by Route of Administration
- 7.3.5.1.3 Market size and forecast, by Sterility
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Therapeutic Area
- 7.3.5.2.2 Market size and forecast, by Route of Administration
- 7.3.5.2.3 Market size and forecast, by Sterility
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Therapeutic Area
- 7.3.5.3.2 Market size and forecast, by Route of Administration
- 7.3.5.3.3 Market size and forecast, by Sterility
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Therapeutic Area
- 7.3.5.4.2 Market size and forecast, by Route of Administration
- 7.3.5.4.3 Market size and forecast, by Sterility
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Therapeutic Area
- 7.3.5.5.2 Market size and forecast, by Route of Administration
- 7.3.5.5.3 Market size and forecast, by Sterility
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Therapeutic Area
- 7.3.5.6.2 Market size and forecast, by Route of Administration
- 7.3.5.6.3 Market size and forecast, by Sterility
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Therapeutic Area
- 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
- 7.4.4 Asia-Pacific Market size and forecast, by Sterility
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Therapeutic Area
- 7.4.5.1.2 Market size and forecast, by Route of Administration
- 7.4.5.1.3 Market size and forecast, by Sterility
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Therapeutic Area
- 7.4.5.2.2 Market size and forecast, by Route of Administration
- 7.4.5.2.3 Market size and forecast, by Sterility
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Therapeutic Area
- 7.4.5.3.2 Market size and forecast, by Route of Administration
- 7.4.5.3.3 Market size and forecast, by Sterility
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Therapeutic Area
- 7.4.5.4.2 Market size and forecast, by Route of Administration
- 7.4.5.4.3 Market size and forecast, by Sterility
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Therapeutic Area
- 7.4.5.5.2 Market size and forecast, by Route of Administration
- 7.4.5.5.3 Market size and forecast, by Sterility
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Therapeutic Area
- 7.4.5.6.2 Market size and forecast, by Route of Administration
- 7.4.5.6.3 Market size and forecast, by Sterility
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Therapeutic Area
- 7.5.3 LAMEA Market size and forecast, by Route of Administration
- 7.5.4 LAMEA Market size and forecast, by Sterility
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Therapeutic Area
- 7.5.5.1.2 Market size and forecast, by Route of Administration
- 7.5.5.1.3 Market size and forecast, by Sterility
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Therapeutic Area
- 7.5.5.2.2 Market size and forecast, by Route of Administration
- 7.5.5.2.3 Market size and forecast, by Sterility
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Therapeutic Area
- 7.5.5.3.2 Market size and forecast, by Route of Administration
- 7.5.5.3.3 Market size and forecast, by Sterility
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Therapeutic Area
- 7.5.5.4.2 Market size and forecast, by Route of Administration
- 7.5.5.4.3 Market size and forecast, by Sterility
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Advanced Pharmacy
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Athenex Pharma Solutions
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 B. Braun Melsungen AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Dougherty's Pharmacy, Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Fresenius SE and Co. KGaA
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Institutional pharmacy solutions
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 ITC compounding pharmacy
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 McGuff Companies, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Nephron pharmaceuticals
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 New Compounding Pharma
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Olympia Compounding Pharmacy
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Panacea Biomatx Inc (Triangle Compounding Pharmacy)
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Pencol compounding pharmacy
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Perrigo Company Plc (Fagron)
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Rx express compounding pharmacy
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 RX3 compounding pharmacy
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Valor Compounding Pharmacy
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 2. COMPOUNDING PHARMACIES MARKET SIZE, FOR PAIN MANAGEMENT, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. COMPOUNDING PHARMACIES MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. COMPOUNDING PHARMACIES MARKET SIZE, FOR HORMONE REPLACEMENT THERAPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. COMPOUNDING PHARMACIES MARKET FOR HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. COMPOUNDING PHARMACIES MARKET SIZE, FOR DERMAL DISORDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. COMPOUNDING PHARMACIES MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. COMPOUNDING PHARMACIES MARKET SIZE, FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. COMPOUNDING PHARMACIES MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. COMPOUNDING PHARMACIES MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. COMPOUNDING PHARMACIES MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 13. COMPOUNDING PHARMACIES MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. COMPOUNDING PHARMACIES MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. COMPOUNDING PHARMACIES MARKET SIZE, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. COMPOUNDING PHARMACIES MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. COMPOUNDING PHARMACIES MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. COMPOUNDING PHARMACIES MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. GLOBAL COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 20. COMPOUNDING PHARMACIES MARKET SIZE, FOR NON-STERILE COMPOUNDING DRUGS, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. COMPOUNDING PHARMACIES MARKET FOR NON-STERILE COMPOUNDING DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. GLOBAL NON-STERILE COMPOUNDING DRUGS COMPOUNDING PHARMACIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 23. COMPOUNDING PHARMACIES MARKET SIZE, FOR STERILE COMPOUNDING DRUGS, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. COMPOUNDING PHARMACIES MARKET FOR STERILE COMPOUNDING DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. GLOBAL STERILE COMPOUNDING DRUGS COMPOUNDING PHARMACIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 26. COMPOUNDING PHARMACIES MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA COMPOUNDING PHARMACIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 31. U.S. COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 32. U.S. COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 33. U.S. COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 34. CANADA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 35. CANADA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 36. CANADA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 37. MEXICO COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 38. MEXICO COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 39. MEXICO COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 40. EUROPE COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 41. EUROPE COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 42. EUROPE COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 43. EUROPE COMPOUNDING PHARMACIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 44. GERMANY COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 45. GERMANY COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 46. GERMANY COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 47. FRANCE COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 48. FRANCE COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 49. FRANCE COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 50. UK COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 51. UK COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 52. UK COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 53. ITALY COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 54. ITALY COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 55. ITALY COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 56. SPAIN COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 57. SPAIN COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 58. SPAIN COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 59. REST OF EUROPE COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 60. REST OF EUROPE COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 62. ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 63. ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 66. JAPAN COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 67. JAPAN COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 68. JAPAN COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 69. CHINA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 70. CHINA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 71. CHINA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 72. INDIA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 73. INDIA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 74. INDIA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 75. AUSTRALIA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 76. AUSTRALIA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 77. AUSTRALIA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 78. SOUTH KOREA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 79. SOUTH KOREA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 80. SOUTH KOREA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 81. REST OF ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 82. REST OF ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 83. REST OF ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 84. LAMEA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 85. LAMEA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 86. LAMEA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 87. LAMEA COMPOUNDING PHARMACIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 88. BRAZIL COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 89. BRAZIL COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 90. BRAZIL COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 91. SAUDI ARABIA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 92. SAUDI ARABIA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 93. SAUDI ARABIA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 94. SOUTH AFRICA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 95. SOUTH AFRICA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 96. SOUTH AFRICA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 97. REST OF LAMEA COMPOUNDING PHARMACIES MARKET, BY THERAPEUTIC AREA, 2021-2031 ($MILLION)
- TABLE 98. REST OF LAMEA COMPOUNDING PHARMACIES MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 99. REST OF LAMEA COMPOUNDING PHARMACIES MARKET, BY STERILITY, 2021-2031 ($MILLION)
- TABLE 100.ADVANCED PHARMACY: COMPANY SNAPSHOT
- TABLE 101.ADVANCED PHARMACY: OPERATING SEGMENTS
- TABLE 102.ADVANCED PHARMACY: PRODUCT PORTFOLIO
- TABLE 103.ADVANCED PHARMACY: NET SALES,
- TABLE 104.ADVANCED PHARMACY: KEY STRATERGIES
- TABLE 105.ATHENEX PHARMA SOLUTIONS: COMPANY SNAPSHOT
- TABLE 106.ATHENEX PHARMA SOLUTIONS: OPERATING SEGMENTS
- TABLE 107.ATHENEX PHARMA SOLUTIONS: PRODUCT PORTFOLIO
- TABLE 108.ATHENEX PHARMA SOLUTIONS: NET SALES,
- TABLE 109.ATHENEX PHARMA SOLUTIONS: KEY STRATERGIES
- TABLE 110.B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
- TABLE 111.B. BRAUN MELSUNGEN AG: OPERATING SEGMENTS
- TABLE 112.B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
- TABLE 113.B. BRAUN MELSUNGEN AG: NET SALES,
- TABLE 114.B. BRAUN MELSUNGEN AG: KEY STRATERGIES
- TABLE 115.DOUGHERTY'S PHARMACY, INC.: COMPANY SNAPSHOT
- TABLE 116.DOUGHERTY'S PHARMACY, INC.: OPERATING SEGMENTS
- TABLE 117.DOUGHERTY'S PHARMACY, INC.: PRODUCT PORTFOLIO
- TABLE 118.DOUGHERTY'S PHARMACY, INC.: NET SALES,
- TABLE 119.DOUGHERTY'S PHARMACY, INC.: KEY STRATERGIES
- TABLE 120.FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
- TABLE 121.FRESENIUS SE AND CO. KGAA: OPERATING SEGMENTS
- TABLE 122.FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
- TABLE 123.FRESENIUS SE AND CO. KGAA: NET SALES,
- TABLE 124.FRESENIUS SE AND CO. KGAA: KEY STRATERGIES
- TABLE 125.INSTITUTIONAL PHARMACY SOLUTIONS: COMPANY SNAPSHOT
- TABLE 126.INSTITUTIONAL PHARMACY SOLUTIONS: OPERATING SEGMENTS
- TABLE 127.INSTITUTIONAL PHARMACY SOLUTIONS: PRODUCT PORTFOLIO
- TABLE 128.INSTITUTIONAL PHARMACY SOLUTIONS: NET SALES,
- TABLE 129.INSTITUTIONAL PHARMACY SOLUTIONS: KEY STRATERGIES
- TABLE 130.ITC COMPOUNDING PHARMACY: COMPANY SNAPSHOT
- TABLE 131.ITC COMPOUNDING PHARMACY: OPERATING SEGMENTS
- TABLE 132.ITC COMPOUNDING PHARMACY: PRODUCT PORTFOLIO
- TABLE 133.ITC COMPOUNDING PHARMACY: NET SALES,
- TABLE 134.ITC COMPOUNDING PHARMACY: KEY STRATERGIES
- TABLE 135.MCGUFF COMPANIES, INC.: COMPANY SNAPSHOT
- TABLE 136.MCGUFF COMPANIES, INC.: OPERATING SEGMENTS
- TABLE 137.MCGUFF COMPANIES, INC.: PRODUCT PORTFOLIO
- TABLE 138.MCGUFF COMPANIES, INC.: NET SALES,
- TABLE 139.MCGUFF COMPANIES, INC.: KEY STRATERGIES
- TABLE 140.NEPHRON PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 141.NEPHRON PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 142.NEPHRON PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 143.NEPHRON PHARMACEUTICALS: NET SALES,
- TABLE 144.NEPHRON PHARMACEUTICALS: KEY STRATERGIES
- TABLE 145.NEW COMPOUNDING PHARMA: COMPANY SNAPSHOT
- TABLE 146.NEW COMPOUNDING PHARMA: OPERATING SEGMENTS
- TABLE 147.NEW COMPOUNDING PHARMA: PRODUCT PORTFOLIO
- TABLE 148.NEW COMPOUNDING PHARMA: NET SALES,
- TABLE 149.NEW COMPOUNDING PHARMA: KEY STRATERGIES
- TABLE 150.OLYMPIA COMPOUNDING PHARMACY: COMPANY SNAPSHOT
- TABLE 151.OLYMPIA COMPOUNDING PHARMACY: OPERATING SEGMENTS
- TABLE 152.OLYMPIA COMPOUNDING PHARMACY: PRODUCT PORTFOLIO
- TABLE 153.OLYMPIA COMPOUNDING PHARMACY: NET SALES,
- TABLE 154.OLYMPIA COMPOUNDING PHARMACY: KEY STRATERGIES
- TABLE 155.PANACEA BIOMATX INC (TRIANGLE COMPOUNDING PHARMACY): COMPANY SNAPSHOT
- TABLE 156.PANACEA BIOMATX INC (TRIANGLE COMPOUNDING PHARMACY): OPERATING SEGMENTS
- TABLE 157.PANACEA BIOMATX INC (TRIANGLE COMPOUNDING PHARMACY): PRODUCT PORTFOLIO
- TABLE 158.PANACEA BIOMATX INC (TRIANGLE COMPOUNDING PHARMACY): NET SALES,
- TABLE 159.PANACEA BIOMATX INC (TRIANGLE COMPOUNDING PHARMACY): KEY STRATERGIES
- TABLE 160.PENCOL COMPOUNDING PHARMACY: COMPANY SNAPSHOT
- TABLE 161.PENCOL COMPOUNDING PHARMACY: OPERATING SEGMENTS
- TABLE 162.PENCOL COMPOUNDING PHARMACY: PRODUCT PORTFOLIO
- TABLE 163.PENCOL COMPOUNDING PHARMACY: NET SALES,
- TABLE 164.PENCOL COMPOUNDING PHARMACY: KEY STRATERGIES
- TABLE 165.PERRIGO COMPANY PLC (FAGRON): COMPANY SNAPSHOT
- TABLE 166.PERRIGO COMPANY PLC (FAGRON): OPERATING SEGMENTS
- TABLE 167.PERRIGO COMPANY PLC (FAGRON): PRODUCT PORTFOLIO
- TABLE 168.PERRIGO COMPANY PLC (FAGRON): NET SALES,
- TABLE 169.PERRIGO COMPANY PLC (FAGRON): KEY STRATERGIES
- TABLE 170.RX EXPRESS COMPOUNDING PHARMACY: COMPANY SNAPSHOT
- TABLE 171.RX EXPRESS COMPOUNDING PHARMACY: OPERATING SEGMENTS
- TABLE 172.RX EXPRESS COMPOUNDING PHARMACY: PRODUCT PORTFOLIO
- TABLE 173.RX EXPRESS COMPOUNDING PHARMACY: NET SALES,
- TABLE 174.RX EXPRESS COMPOUNDING PHARMACY: KEY STRATERGIES
- TABLE 175.RX3 COMPOUNDING PHARMACY: COMPANY SNAPSHOT
- TABLE 176.RX3 COMPOUNDING PHARMACY: OPERATING SEGMENTS
- TABLE 177.RX3 COMPOUNDING PHARMACY: PRODUCT PORTFOLIO
- TABLE 178.RX3 COMPOUNDING PHARMACY: NET SALES,
- TABLE 179.RX3 COMPOUNDING PHARMACY: KEY STRATERGIES
- TABLE 180.VALOR COMPOUNDING PHARMACY: COMPANY SNAPSHOT
- TABLE 181.VALOR COMPOUNDING PHARMACY: OPERATING SEGMENTS
- TABLE 182.VALOR COMPOUNDING PHARMACY: PRODUCT PORTFOLIO
- TABLE 183.VALOR COMPOUNDING PHARMACY: NET SALES,
- TABLE 184.VALOR COMPOUNDING PHARMACY: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.COMPOUNDING PHARMACIES MARKET SEGMENTATION
- FIGURE 2.COMPOUNDING PHARMACIES MARKET,2021-2031
- FIGURE 3.COMPOUNDING PHARMACIES MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.COMPOUNDING PHARMACIES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.COMPOUNDING PHARMACIES MARKET,BY THERAPEUTIC AREA,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PAIN MANAGEMENT COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF HORMONE REPLACEMENT THERAPY COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF DERMAL DISORDERS COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF NUTRITIONAL SUPPLEMENTS COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 18.COMPOUNDING PHARMACIES MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ORAL COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF TOPICAL COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 22.COMPOUNDING PHARMACIES MARKET,BY STERILITY,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF NON-STERILE COMPOUNDING DRUGS COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF STERILE COMPOUNDING DRUGS COMPOUNDING PHARMACIES MARKET,2021-2031(%)
- FIGURE 25.COMPOUNDING PHARMACIES MARKET BY REGION,2021
- FIGURE 26.U.S. COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 27.CANADA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 28.MEXICO COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 29.GERMANY COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 30.FRANCE COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 31.UK COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 32.ITALY COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 33.SPAIN COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 34.REST OF EUROPE COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 35.JAPAN COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 36.CHINA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 37.INDIA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 38.AUSTRALIA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 39.SOUTH KOREA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 40.REST OF ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 41.BRAZIL COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 42.SAUDI ARABIA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 43.SOUTH AFRICA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 44.REST OF LAMEA COMPOUNDING PHARMACIES MARKET,2021-2031($MILLION)
- FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 49.COMPETITIVE DASHBOARD
- FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 51.ADVANCED PHARMACY.: NET SALES ,($MILLION)
- FIGURE 52.ATHENEX P
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook